Wildhirt S M, Weis M, Schulze C, Conrad N, Rieder G, Enders G, Ihnken K, von Scheidt W, Reichart B
Department of Cardiac Surgery, Grosshadern Hospital, Ludwig-Maximilians University, Munich, Germany.
Transpl Int. 2000;13 Suppl 1:S203-11. doi: 10.1007/s001470050326.
Optimal preservation of the myocardium remains a major concern in clinical and experimental heart transplantation. The present study compared the efficacy of University of Wisconsin (UW) and Celsior preservation solution with respect to myocardial performance, epicardial and microvascular endothelial vasomotor function and myocardial expression of endothelin and nitric oxide synthases in humans. Forty-one cardiac transplant recipients received either UW (n = 20) or Celsior (n = 21) preserved hearts. Catecholamine and vasodilator requirements were assessed within the first 5 postoperative days. Left ventricular performance and endothelial function was assessed 1 month after transplantation. Endothelin and nitric oxide synthase gene expression were detected in myocardial biopsy samples. Celsior preserved hearts required significantly more catecholamines and vasodilators within the first 5 postoperative days. Myocardial performance and endothelial function were comparable 1 month after transplantation. Total ischemic time correlated with impaired endothelial function in the Celsior but not in the UW group. Endothelin and inducible nitric oxide synthase gene expression were significantly higher in the Celsior group. The results of the study show that both solutions provide myocardial protection with regard to left ventricular performance and endothelial function 1 month after cardiac transplantation. The necessity for higher vasodilator and catecholamine therapy in Celsior preserved hearts suggests post-ischemic myocardial stunning within the first 5 postoperative days. The positive correlation between impaired endothelial function and total ischemic time in the Celsior group requires longitudinal investigation in particular with regard to the development of allograft vasculopathy.
在临床和实验性心脏移植中,心肌的最佳保存仍然是一个主要问题。本研究比较了威斯康星大学(UW)保存液和赛尔修斯(Celsior)保存液在人类心肌性能、心外膜和微血管内皮血管舒缩功能以及内皮素和一氧化氮合酶心肌表达方面的效果。41名心脏移植受者接受了UW(n = 20)或Celsior(n = 21)保存的心脏。在术后第1个5天内评估儿茶酚胺和血管扩张剂的需求。在移植后1个月评估左心室性能和内皮功能。在心肌活检样本中检测内皮素和一氧化氮合酶基因表达。Celsior保存的心脏在术后第1个5天内需要显著更多的儿茶酚胺和血管扩张剂。移植后1个月心肌性能和内皮功能相当。总缺血时间与Celsior组但非UW组的内皮功能受损相关。Celsior组内皮素和诱导型一氧化氮合酶基因表达显著更高。研究结果表明,两种保存液在心脏移植后1个月对左心室性能和内皮功能均提供心肌保护。Celsior保存的心脏需要更高剂量血管扩张剂和儿茶酚胺治疗,提示术后第1个5天内存在缺血后心肌顿抑。Celsior组内皮功能受损与总缺血时间之间的正相关需要进行纵向研究,特别是关于移植血管病变的发展。